PuraPharm (HKSE:01498) Additional Paid-In Capital : HK$0.0 Mil(As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PuraPharm Additional Paid-In Capital?

PuraPharm's quarterly additional paid-in capital stayed the same from Dec. 2022 (HK$221.6 Mil) to Jun. 2023 (HK$221.6 Mil) and stayed the same from Jun. 2023 (HK$221.6 Mil) to Dec. 2023 (HK$0.0 Mil).

PuraPharm's annual additional paid-in capital increased from Dec. 2021 (HK$221.2 Mil) to Dec. 2022 (HK$221.6 Mil) but then declined from Dec. 2022 (HK$221.6 Mil) to Dec. 2023 (HK$0.0 Mil).

PuraPharm Additional Paid-In Capital Historical Data

The historical data trend for PuraPharm's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Additional Paid-In Capital Chart

PuraPharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

221.19

221.57

PuraPharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															221.19	-	221.57	221.57	-

PuraPharm Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

PuraPharm Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of PuraPharm's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

PuraPharm (HKSE:01498) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines